Pharmacokinetics, Pharmacodynamics, Bioequivalence

As a service to the pharmaceutical industry, we investigate the pharmacokinetics (PK) and pharmacodynamics (PD) of new drugs as well as the bioequivalence (BE) of new pharmaceutical formulations. We also carry out biomarker-based and metabolomic studies to pinpoint the causes of inflammatory diseases. We perform preclinical ex vivo and in vivo, as well as clinical in vivo, studies. During these studies, we use microdialysis and our patented Open Flow Microperfusion (OFM).

Reference Projects
  • Tec.Reg:
    Technologies for Regenerative Medicine

  • Smart4fabry:
    Smart functional GLA nanoformulation for Fabry disease
  • IDT4Brain:
    Improved diagnosis and treatment for neurodegenerative diseases by directly accessing tissues in the brain

  • PK-PD of Antibody:
    Pharmacokinetics und pharmacodynamics of an antibody in the skin of healthy volunteers and psoriatric patients

  • FDA-Project:
    Bioequivalence of drugs in the skin